IgG4 Binding Agent Formulation Stabilization via Citrate Buffer pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating anti-LIGHT and anti-CXCR5 binding agents at high concentrations is complicated by issues such as increased viscosity, pH shift, color change, and formation of particles, as well as aggregation and half-molecule formation, which are particularly challenging for IgG4 antibodies due to their therapeutic interest despite reduced effector function.
Innovation Solution
Development of highly stable IgG4 binding agent formulations comprising an IgG4 binding agent and a citrate buffer, with a pH at or below the isoelectric point of the binding agent, reducing unwanted byproducts like aggregates, half-molecules, and degradation products, and incorporating surfactants and tonicity agents to maintain stability and effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the concentration of IgG4 binding agent is increased to 20 mg/mL or greater for therapeutic efficacy, then the therapeutic effectiveness is improved, but aggregation and half-molecule formation occur
Solution Approach 1:
The patent changes the pH parameter of the formulation to be at or below the isoelectric point of the IgG4 binding agent (pH ≤ pI). This parameter change prevents aggregation and half-molecule formation while maintaining high concentrations (20-250 mg/mL) of the binding agent, thereby resolving the contradiction between concentration and stability.
Solution Approach 2:
The patent introduces citrate buffer as an intermediary substance to maintain the pH at or below the isoelectric point. This intermediary prevents direct interactions that lead to aggregation, allowing high concentrations of binding agent to remain stable for intravenous or subcutaneous administration.
2Productivity
If the concentration of IgG4 binding agent is increased to reduce dosing volume, then the dosing efficiency is improved, but viscosity increases
Solution Approach 1:
By adjusting the pH to be at or below the isoelectric point using citrate buffer, the patent reduces intermolecular interactions that cause viscosity increase. This allows formulation at high concentrations (20-250 mg/mL) while maintaining acceptable viscosity for intravenous or subcutaneous injection, thereby improving dosing efficiency without excessive viscosity.
3Productivity
If the concentration of IgG4 binding agent is increased to reduce manufacturing cost per dose, then the manufacturing efficiency is improved, but pH shifts occur
Solution Approach 1:
The patent uses citrate buffer as an intermediary to control and stabilize pH at or below the isoelectric point of the binding agent. This buffer system prevents pH shifts that normally occur at high concentrations (20-250 mg/mL), enabling cost-effective high-concentration formulations while maintaining compositional stability for therapeutic administration.
4Device complexity
If conventional formulations are used to simplify the formulation process, then the manufacturing complexity is reduced, but dimerization of the binding agent occurs
Solution Approach 1:
The patent changes the pH parameter to be at or below the isoelectric point and uses citrate buffer instead of conventional buffers. This simple parameter change prevents dimerization of the IgG4 binding agent while maintaining formulation simplicity suitable for manufacturing, thereby resolving the contradiction between formulation simplicity and prevention of dimerization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide improved stability and reduced byproduct formation, maintaining the therapeutic efficacy of IgG4 antibodies at high concentrations, suitable for both liquid and lyophilized forms, and suitable for intravenous or subcutaneous administration, with enhanced stability and reduced aggregation.
Implementation Method 1
the pH of the formulation is at or below both about pH 6 and the isoelectric point (pI) of the binding agent
Data Source
AI summary
The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.